Ionizable lipid compound and use thereof in field of nucleic acid delivery

By optimizing the structure of ionizable lipid compounds, combining auxiliary lipids and PEG lipids, it forms efficient lipid nanoparticles, solving the problem of low delivery efficiency of mRNA drugs in the body and achieving efficient and low-toxic nucleic acid delivery effects .

WO2024240133A1PCT designated stage expired Publication Date: 2024-11-28HANGZHOU NEOANTIGEN THERAPEUTICS CO LTD

Patent Information

Application Number
PCT/CN2024/094360
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Among the existing nucleic acid drug delivery technologies, especially mRNA drugs, due to their large molecular weight and strong negative electrical properties, they are difficult to be stable and cell membrane penetration, resulting in low delivery efficiency in bulk, and ionizable lipid compounds limit the development of lipid nanoparticles. .

Method used

New ionizable lipid compounds are adopted, and their structures are improved by introducing pyridine groups and optimizing amino heads, combining auxiliary phospholipids and cholesterol with PEG lipids to form efficient lipid nanoparticles, improving the wrapping and delivery capabilities of nucleic acids.

Benefits of technology

It significantly improves the cell transfection efficiency and in vivo delivery efficiency of nucleic acid drugs, reduces toxic side effects, and provides an efficient and low-toxic nucleic acid delivery solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094360_28112024_PF_FP_ABST
    Figure CN2024094360_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine. Particularly, disclosed are an ionizable lipid compound and a use thereof in the field of nucleic acid delivery. The ionizable lipid compound of the present invention is a compound having the following structure: (I), wherein G1 is pyridine, quinoline, or a derivative thereof. A synthesis method for the compound of the present invention is mild in condition, and the product yield of a synthetic route is high. The LNPs prepared from the compound of the present invention have an excellent lysosomal escape ability, high nucleic acid delivery efficiency, low toxicity and high safety, and have an important application value.
Need to check novelty before this filing date? Find Prior Art

Description

Ionizable lipid compounds and their applications in nucleic acid delivery Technical Field

[0001] The present invention relates to the fields of biomedicine and pharmaceutical preparation, in particular to an ionizable lipid compound and its application in the field of nucleic acid delivery. Background Art

[0002] Nucleic acids, including small interfering RNA (siRNA), messenger RNA (mRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), plasmids, and immunostimulatory nucleic acids, can exert regulatory effects through a variety of mechanisms. For example, in the cytoplasm, ribosomes bind to mRNA molecules and convert specific nucleotide sequences into amino acid sequences. mRNA does not require entry into the cell nucleus, thus posing no risk of genetic mutations. mRNA drugs offer numerous advantages, including a short development cycle, a wide selection of antigens, high safety, low doses, and stable expression. However, mRNA drugs face two biological barriers regarding their mechanism of action. First, when nucleic acid drugs enter the human body, their large molecular weight results in a multitude of attack and destruction sites, leading to poor stability and susceptibility to degradation within the body. Furthermore, mRNA itself is highly negatively charged and hydrophilic, making it difficult to cross cell membranes, resulting in extremely low in vivo delivery efficiency. Effectively delivering mRNA into cells is crucial for achieving its therapeutic efficacy.

[0003] Status and shortcomings of existing technology:

[0004] At present, the most widely used and mature nucleic acid drug delivery technology is lipid nanoparticles (LNP), which can protect nucleic acids from rapid degradation in the body, prolong circulation time, and help drugs break through extracellular and intracellular barriers to exert their efficacy. LNP is generally composed of four components, including ionizable / cationic lipids, PEG-modified lipids, auxiliary phospholipids and cholesterol. Among them, ionizable lipids play the most important role. On the one hand, this compound can effectively load nucleic acid drugs, and on the other hand, it can be protonated in a specific acidic environment, thereby improving the ability to escape from lysosomes. Ionizable lipid compounds are still the main constraint limiting the development of high-performance LNPs. Therefore, the development of a new, efficient, and low-toxic ionizable lipid has important application value.

[0005] Summary of the Invention

[0006] To address the deficiencies of the prior art, the present invention aims to provide an ionizable lipid compound and its application in the field of nucleic acid delivery. The compound synthesis method of the present invention has mild conditions and a synthetic route with a high product yield. The LNP prepared from the compound of the present invention has a high lysosomal escape ability, high nucleic acid delivery efficiency, low toxicity and high safety, and has important application value.

[0007] In order to achieve the above objectives, the present invention adopts the following technical solutions:

[0008] The ionizable lipid compound is a compound having the following structure:

[0009] G1 is pyridine, quinoline or its derivatives;

[0010] L1 is selected from:

[0011] G2 is the structural formula of the following formula (2) and (3):

[0012] wherein L2 is a C3-C9 alkylene group; R1 and R2 are each independently a C3-C9 alkyl group;

[0013] G3 is the structural formula of the following formula (4) and (5):

[0014] wherein L3 is a C3-C9 alkylene group; and R3 and R4 are each independently a C3-C9 alkyl group. The aforementioned ionizable lipid compound, wherein -C(R1)R2 or -C(R3)R4 is selected from the following structures:

[0015] The aforementioned ionizable lipid compounds include the following compounds:

[0016] The present disclosure provides ionizable lipid compounds for use in preparing carriers of active ingredients. In some embodiments, the carrier is in the form of lipid nanoparticles, such as lipid bilayers, micelles, liposomes, etc. Within the scope of the present disclosure, the term "lipid nanoparticle" means a nanometer-sized substance prepared by placing an ionizable or cationic lipid compound in an aqueous solution. These particles are particularly lipid nanoparticles, lipid bilayer vesicles (liposomes), multilamellar vesicles or micelles.

[0017] The present disclosure provides lipid nanoparticles containing the ionizable lipid compounds of the present disclosure and a pharmaceutically acceptable carrier, diluent, or excipient.

[0018] In some embodiments, the lipid nanoparticles further contain one or more of a helper lipid, a structural lipid, and a PEG lipid (polyethylene glycol-lipid).

[0019] The aforementioned use of the ionizable lipid compound in the field of delivery is applied to a composition comprising the ionizable lipid compound, its stereoisomers, its tautomers or pharmaceutically acceptable salts thereof.

[0020] The aforementioned application of the ionizable lipid compound in the field of delivery, the composition containing the ionizable lipid compound includes: nucleic acid active molecules, lipid nanoparticles encapsulating the nucleic acid active molecules, and pharmaceutical agents.

[0021] In some embodiments, the lipid nanoparticles comprise the following amount (molar percentage) of the ionizable lipid compound, based on the total amount of the ionizable lipid compound, the helper lipid, the structural lipid, and the PEG lipid: about 30.0%-50.0%, for example, about 30.0%-32.0%, 32.0%-35.0%, 35.0%-40.0%, 40.0%-42.0%, 42.0%-45.0%, 45.0%-46.5%, 46.5%-48.0%, 48.0%-49.5%, or 49.5%-50.0%.

[0022] In some embodiments, the lipid nanoparticles comprise the helper lipid in the following amount (molar percentage), based on the total amount of the ionizable lipid compound, the helper lipid, the structural lipid, and the PEG lipid: about 8.0%-12.0%, for example, about 8.0%-9.0%, 9.0%-9.5%, 9.5%-10.0%, 10.0%-10.5%, 10.5%-11.0%, or 11.0%-12.0%.

[0023] In some embodiments, the lipid nanoparticles comprise the following amount (molar percentage) of the structural lipid, based on the total amount of the ionizable lipid compound, the helper lipid, the structural lipid, and the PEG lipid: about 35.0%-60.0%, for example, about 35.0%-36.5%, 36.5%-38.0%, 38.0%-38.5%, 38.5%-39.0%, 39.0%-39.5%, 39.5%-40.5%, 40.5%-41. .5%, 41.5%-42.5%, 42.5%-42.7%, 42.7%-43.0%, 43.0%-43.5%, 43.5%-45.0%, 45.0%-46.5%, 46.5%-48.5%, 48.5%-50.0%, 50.0%-51.5%, 51.5%-53.0%, 53.0%-54.5%, 54.5%-56.0%, 56.0%-57.5%, or 57.5%-60.0%.

[0024] In some embodiments, the lipid nanoparticles comprise the following amount (molar percentage) of the PEG lipid, based on the total amount of the ionizable lipid compound, the helper lipid, the structural lipid, and the PEG lipid: about 1.0%-3.0%, for example, about 1.0%-1.5%, 1.5%-1.6%, 1.6%-2.0%, 2.0%-2.5%, or 2.5%-3.0%.

[0025] In some embodiments, the aforementioned ionizable lipid compounds are used in the field of delivery, and the lipid nanoparticles include, by molar percentage, 30-50% of one or more ionizable lipid compounds, 8-12% of auxiliary phospholipids, 35-60% of structural lipids, and 1-3% of PEG lipids.

[0026] In the aforementioned application of an ionizable lipid compound, the auxiliary phospholipid is a phospholipid. The phospholipid is typically semi-synthetic, but may also be of natural origin or chemically modified. The phospholipid includes, but is not limited to, DSPC (distearoylphosphatidylcholine), DOPE (dioleoylphosphatidylethanolamine), DOPC (dioleoylphosphatidylcholine), DOPS (dioleoylphosphatidylserine), DSPG (1,2-dioctadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol)), DPPG (dipalmitoylphosphatidylglycerol), DPPC (dipalmitoylphosphatidylcholine), DGTS (1,2-dipalmitoyl-sn-glycero-3-O-4'-(N,N,N-trimethyl)homoserine), lysophospholipids, and the like. Preferably, the auxiliary lipid is one or more selected from DSPC, DOPE, DOPC, and DOPS. In some embodiments, the auxiliary lipid is DSPC and / or DOPE.

[0027] In the aforementioned application of an ionizable lipid compound, the structural phospholipid is a sterol substance, including but not limited to cholesterol, cholesterol esters, sterol hormones, sterol vitamins, bile acids, cholesterol, ergosterol, β-sitosterol, and oxidized cholesterol derivatives. Preferably, the structural lipid is at least one selected from cholesterol, cholesterol esters, sterol hormones, sterol vitamins, and bile acids. In some embodiments, the structural lipid is cholesterol, preferably high-purity cholesterol, particularly injection-grade high-purity cholesterol, such as CHO-HP.

[0028] The aforementioned application of an ionizable lipid compound, wherein the PEG lipid (polyethylene glycol-lipid) is a conjugate of polyethylene glycol and a lipid structure. Preferably, the PEG-lipid is selected from DMG-PEG, distearoyl-rac-glycerol-polyethylene glycol (DSG-PEG), distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG), preferably DMG-PEG. Preferably, the DMG-PEG is a polyethylene glycol (PEG) derivative of 1,2-dimyristyl glycerol. Preferably, the average molecular weight of the PEG is about 2000 to 5000, preferably about 2000.

[0029] In the aforementioned application of an ionizable lipid compound, the nucleic acid active molecule is selected from mRNA, siRNA, ASO, saRNA, miRNA, and DNA.

[0030] The aforementioned application of ionizable lipid compounds in the field of nucleic acid delivery is achieved by preparing LNPs as follows: dissolving ionizable lipid chemicals, auxiliary phospholipids, cholesterol, and PEG lipids in ethanol to obtain a lipid ethanol solution; and mixing the lipid ethanol solution with a nucleic acid aqueous solution through a device mixing device to obtain lipid nanoparticles encapsulating nucleic acids.

[0031] The present invention is beneficial in that:

[0032] 1. By improving the amino head structure of ionizable lipids and introducing a pyridine group, a new type of ionizable lipid structure was obtained.

[0033] 2. The structure-activity relationship was clarified. When L1 is a methylene group, it was confirmed that the ionizable lipids substituted at the 3rd position (meta position) of the pyridine group have significantly enhanced cell transfection efficiency. It was also confirmed that methyl substitution at the 6th position of the pyridine group can further enhance the cell transfection efficiency of the ionizable lipids.

[0034] 3. Combining this type of ionizable lipid compound with auxiliary phospholipids, cholesterol and PEG lipids can obtain lipid nanoparticles with uniform size and good stability, and can also efficiently and stably encapsulate nucleic acid active molecules.

[0035] 4. Compared with the commercialized SM102-LNP or MC3 LNP, the LNP containing the novel ionizable lipid compound proposed in the present invention has more efficient in vitro and in vivo cellular translation expression levels, thereby improving the efficiency of nucleic acid molecule delivery.

[0036] 5. From the mouse experiment, it can be seen that the LNP containing the new pyridyl ionizable lipid proposed in this patent invention has little toxic side effects on mice, the mice survive well, and are safe. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 is a cryo-electron micrograph of L-9-LNP / mRNA.

[0038] FIG2 is a graph showing the transfection efficiency of L-1-LNP to L-5-LNP on DC2.4 cells.

[0039] FIG3 is a graph showing the transfection efficiency of L-6-LNP to L-12-LNP on DC2.4 cells.

[0040] FIG4 is a graph showing the transfection efficiency of L-13-LNP to L-19-LNP on DC2.4 cells.

[0041] FIG5 is a graph showing the transfection efficiency of L-20-LNP to L-33-LNP on DC2.4 cells.

[0042] FIG6 is a graph showing the transfection effects of L-37-LPX and CX-LPX (X=3, 4, 5) on 293T cells.

[0043] FIG7 is a graph showing the transfection efficiency of ortho-, meta-, and para-substituted ionizable lipids in 293T cells.

[0044] FIG8 is a graph showing the transfection efficiency of ionizable lipids with an additional methyl group substituted at position 6 in 293T cells.

[0045] FIG9 is a graph showing the expression efficiency of Fluc-mRNA delivered by LX-LNP and SM102 LNP in vivo. DETAILED DESCRIPTION

[0046] The present invention will be described in detail below with reference to the accompanying drawings and specific embodiments.

[0047] Example 1, Synthesis of Lipid Compound L-1

[0048] Compound 1-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 3.35 g), 4-dimethylaminopyridine (DMAP, 1.64 g) and compound 1-2 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 1-3.

[0049] Compound 1-4 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask. EDCI (3.35 g), DMAP (1.64 g) and compound 1-5 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 1-6.

[0050] Compound 1-7 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70° C. for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 1-8.

[0051] Compound 1-8 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-1 (600 mg, 76.9% yield). 1 H NMR(400MHz,Chloroform-d)δ8.45-8.59(m,1H),7.66(m,1H),7.16-7.22(m,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),2.69 -2.72(m,2H),2.36-2.40(m,6H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0052] Example 2, Synthesis of Lipid Compound L-2

[0053] Compound 2-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 2-2.

[0054] Compound 2-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-2 (550 mg, 70.1% yield). 1 H NMR(400MHz,Chloroform-d)δ8.41-8.44(m,2H),7.46-7.50(m,1H),7.16-7.18(m,1H),4.45-4.49(m,1H),4.10-1.15(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,6H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0055] Example 3, Synthesis of Lipid Compound L-3

[0056] Compound 3-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 3-2.

[0057] Compound 3-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-3 (500 mg, 63.7% yield). 1H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.06-7.08(d,2H),4.45-4.49(m,1H),4 .10-1.15(m,2H),2.69-2.72(m,2H),2.36-2.40(m,6H),2.30-2.34(m,4H),1.60-1.66(m, 8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0058] Example 4, Synthesis of Lipid Compound L-4

[0059] Compound 4-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 4-2.

[0060] Compound 4-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-4 (516 mg, 65.8% yield). 1 H NMR(400MHz,Chloroform-d)δ7.21-7.25(s,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.40-3.42(m,2H),2.66-2.70 (s,6H),2.40-2.42(m,6H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0061] Example 5, Synthesis of Lipid Compound L-5

[0062] Compound 5-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 5-2.

[0063] Compound 5-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then weighed and added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-5 (534 mg, 64.0% yield). 1 H NMR(400MHz,Chloroform-d)δ8.08-8.12(d,1H),7.99-8.02(d,1H),7.79-7.83(t, 1H),7.62-7.66(t,1H),7.47-7.51(t,1H),7.28-7.32(d,1H),4.45-4.49(m,1H),4 .10-1.15(m,2H),3.40-3.42(m,2H),2.66-2.70(s,6H),2.40-2.42(m,6H),2.30-2 .34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0064] Example 6, Synthesis of Lipid Compound L-6

[0065] Compound 6-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 6-2.

[0066] Compound 6-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then weighed and added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed by rotary evaporation to obtain lipid compound L-6 (610 mg, 80% yield). 1H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),3 .00-3.02(m,4H),2.69-2.71(t,2H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0067] Example 7, Synthesis of Lipid Compound L-7

[0068] Compound 7-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 7-2.

[0069] Compound 7-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-7 (555 mg, 71.9% yield). 1 H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),2.75-2.79(m,2H),2 .41-2.43(m,6H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),1.21-1.23(m,3H),0.89(d,9H).

[0070] Example 8, Synthesis of Lipid Compound L-8

[0071] Compound 8-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 8-2.

[0072] Compound 8-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-8 (480 mg, 59.0% yield). 1 H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),2.75-2.79(m, 2H),2.41-2.43(m,6H),2.30-2.34(m,4H),1.60-1.66(m,8H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.88-0.89(d,18H).

[0073] Example 9, Synthesis of Lipid Compound L-9

[0074] Compound 9-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 9-2.

[0075] Compound 9-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then weighed and added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-9 (510 mg, 66% yield). 1H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.39-3.43(m,2H),2.99 -3.03(m,4H),2.44-2.48(m,2H),2.30-2.34(m,4H),1.93-1.96(m,2H),1.60-1.66(m,6H),1.26-1.49(m,54H),0.88-0.89(d,9H).

[0076] Example 10, Synthesis of Lipid Compound L-10

[0077] Compound 10-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 10-2.

[0078] Compound 10-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-10 (560 mg, 71.4% yield). 1 H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),2.99-3.03(m, 4H),2.53-2.57(m,1H),2.41-2.45(m,2H),2.30-2.34(m,4H),1.66-1.69(m,8H),1.26-1.49(m,54H),0.88-0.89(d,9H).

[0079] Example 11, Synthesis of Lipid Compound L-11

[0080] Compound 11-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified on a silica gel column, and the solvent was removed using a rotary evaporator to obtain compound 11-2.

[0081] Compound 11-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-11 (540 mg, 72.6% yield). 1 H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.43-4.45(m,2H),4.10-1.15(m, 2H),2.46-2.48(m,4H),2.30-2.34(m,4H),1.60-1.66(m,6H),1.26-1.43(m,54H),0.88-0.89(d,9H).

[0082] Example 12, Synthesis of Lipid Compound L-12

[0083] Compound 12-1 (12 mmol) and compound 1-6 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate. After purification on a silica gel column, the solvent was removed using a rotary evaporator to obtain compound 12-1.

[0084] Compound 12-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-12 (500 mg, 62.5% yield). 1H NMR(400MHz,Chloroform-d)δ8.54-8.56(d,2H),7.21-7.23(d,2H),4.43-4.45(m,1H),4.10-1.15(m, 2H),2.52-2.72(m,3H),1.97-1.99(m,1H),1.60-1.66(m,6H),1.26-1.43(m,54H),0.88-0.89(d,9H).

[0085] Example 13, Synthesis of Lipid Compound L-13

[0086] Compound 13-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 13-2 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 13-3.

[0087] Compound 6-1 (12 mmol) and compound 13-3 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 13-4.

[0088] Compound 13-4 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-13 (600 mg, 75.0% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,54H),0.89(d,9H).

[0089] Example 14, Synthesis of Lipid Compound L-14

[0090] Compound 1-4 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 14-1 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 14-2.

[0091] Compound 6-1 (12 mmol) and compound 14-2 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 14-3.

[0092] Compound 14-3 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-14 (575 mg, 73.3% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,52H),0.89(d,9H).

[0093] Example 15, Synthesis of Lipid Compound L-15

[0094] Compound 1-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 1-5 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 15-1.

[0095] Compound 6-1 (12 mmol) and compound 15-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified on a silica gel column, and the solvent was removed using a rotary evaporator to obtain compound 15-2.

[0096] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-15 (600 mg, 75.0% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4 .10-1.15(m,2H),3.43-3.47(m,2H),2.69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m, 4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,50H),0.89(d,9H).

[0097] Example 16, Synthesis of Lipid Compound L-16

[0098] Compound 16-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 16-2 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 16-3.

[0099] Compound 6-1 (12 mmol) and compound 16-3 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 16-4.

[0100] Compound 16-4 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-16 (566 mg, 72.5% yield). 1H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,46H),0.89(d,9H).

[0101] Example 17, Synthesis of Lipid Compound L-17

[0102] Compound 13-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 17-1 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 17-2.

[0103] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-17 (520 mg, 67.4% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,50H),0.89(d,9H).

[0104] Example 18, Synthesis of Lipid Compound L-18

[0105] Compound 16-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 18-1 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 18-2.

[0106] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 18-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-18 (490 mg, 63.5% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,50H),0.89(d,9H).

[0107] Example 19, Synthesis of Lipid Compound L-19

[0108] Compound 19-1 (10 mmol) was dissolved in 10 ml of DCM in a round-bottom flask, and EDCI (3.35 g), DMAP (1.64 g) and compound 19-2 (11 mmol) were added to the reaction system in sequence. After reacting at room temperature for 2 hours, the mixture was purified by silica gel column and rotary evaporation to obtain compound 19-3.

[0109] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 19-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-19 (500 mg, 64.5% yield). 1H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,1H),4.10-1.15(m,2H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.6(m,6H),1.47-1.49(m,6H),1.26-1.33(m,50H),0.89(d,9H).

[0110] Example 20, Synthesis of Lipid Compound L-20

[0111] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 13-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-20 (510 mg, 55.9% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,2H),3.43-3.47(m,2H),2.69-2.72 (m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.68(m,4H),1.47-1.49(m,8H),1.26-1.33(m,68H),0.89(d,9H).

[0112] Example 21, Synthesis of Lipid Compound L-21

[0113] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 15-1 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-21 (523 mg, 57.4% yield). 1H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,2H),3.43-3.47(m,2H),2.69-2.72 (m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.68(m,4H),1.47-1.49(m,8H),1.26-1.33(m,56H),0.89(d,9H).

[0114] Example 22, Synthesis of Lipid Compound L-22

[0115] Compound 15-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 16-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-21 (545 mg, 63.7% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.45-4.49(m,2H),3.43-3.47(m,2H),2.69-2.72 (m,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.68(m,4H),1.47-1.49(m,8H),1.26-1.33(m,56H),0.89(d,9H).

[0116] Example 23, Synthesis of Lipid Compound L-23

[0117] Compound 6-1 (12 mmol) and compound 1-3 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 23-1.

[0118] Compound 23-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 1-3 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-24 (450 mg, 69.7% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.13-4.15(m,4H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.33-2.38(m,8H),1.60-1.66(m,8H),1.47-1.49(m,4H),1.26-1.33(m,34H),0.89(d,6H).

[0119] Example 24, Synthesis of Lipid Compound L-24

[0120] Compound 23-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 18-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-24 (450 mg, 69.7% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.13-4.15(m,4H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.33-2.38(m,8H),1.60-1.66(m,8H),1.47-1.49(m,4H),1.26-1.33(m,34H),0.89(d,6H).

[0121] Example 25, Synthesis of Lipid Compound L-25

[0122] Compound 23-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-25 (430 mg, 66.6% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(d,2H),7.08-7.10(d,2H),4.13-4.15(m,4H),3.43-3.47(m,2H),2 .69-2.72(m,2H),2.33-2.38(m,8H),1.60-1.66(m,8H),1.47-1.49(m,4H),1.26-1.33(m,34H),0.89(d,6H).

[0123] Example 26, Synthesis of Lipid Compound L-26

[0124] 1 mmol of compound 3-1 and 2.4 mmol of compound 26-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-26 (510 mg, 75.6% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,2H),7.08-7.10(m,2H),3.44-3.46(m,4H),2.37-2.43 (m,6H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,44H),0.89(d,6H).

[0125] Example 27, Synthesis of Lipid Compound L-27

[0126] 1 mmol of compound 3-1 and 2.4 mmol of compound 27-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-27 (412 mg, 65.4% yield). 1H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,2H),7.08-7.10(m,2H),3.44-3.46(m,4H),2.37-2.43 (m,6H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,50H),0.89(d,6H).

[0127] Example 28, Synthesis of Lipid Compound L-28

[0128] 1 mmol of compound 3-1 and 2.4 mmol of compound 28-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-28 (412 mg, 60% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,2H),7.08-7.10(m,2H),3.44-3.46(m,4H),2.37-2.43 (m,6H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,58H),0.89(d,6H).

[0129] Example 29, Synthesis of Lipid Compound L-29

[0130] 1 mmol of compound 3-1 and 2.4 mmol of compound 29-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-29 (464 mg, 65% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,2H),7.08-7.10(m,2H),3.44-3.46(m,4H),2.37-2.43 (m,6H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,62H),0.89(d,6H).

[0131] Example 30, Synthesis of Lipid Compound L-30

[0132] 1 mmol of compound 1-7 and 2.4 mmol of compound 28-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-30 (510 mg, 74.2% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,1H),7.65-7.68(m,1H),7.16-7.22(m,2H),3.44-3.46(m,2H),2.69-2.72 (m,2H),2.37-2.43(m,6H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,58H),0.89(d,6H).

[0133] Example 31, Synthesis of Lipid Compound L-31

[0134] 1 mmol of compound 2-1 and 2.4 mmol of compound 28-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-31 (500 mg, 72.7% yield). 1 H NMR(400MHz,Chloroform-d)δ8.42-8.46(m,2H),7.45-7.47(m,1H),7.15-7.17(m,1H),3.44-3.46(m,2H),2.69-2.72 (m,2H),2.37-2.43(m,4H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,58H),0.89(d,6H).

[0135] Example 32, Synthesis of Lipid Compound L-32

[0136] 1 mmol of compound 4-1 and 2.4 mmol of compound 28-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-32 (490 mg, 71.3% yield).1 H NMR(400MHz,Chloroform-d)δ7.21-7.23(s,2H),3.42-3.46(m,4H),2.67-2.69(m,6H),2.37-2.62 (m,4H),2.14-2.15(s,2H),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,58H),0.89(d,6H).

[0137] Example 33, Synthesis of Lipid Compound L-33

[0138] 1 mmol of compound 5-1 and 2.4 mmol of compound 28-1 were added to a Teflon-lined glass screw-cap vial. 2 mL of ACN solvent was added, mixed thoroughly, and then hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compound L-33 (440 mg, 59.7% yield). 1 H NMR(400MHz,Chloroform-d)δ8.09-8.11(m,1H),8.00-8.02(m,1H),7.80-7.82(m,1H),7.61-7.64(m,1H),7.47-7.51(m,1H),7.29-7.31(m,1H),3 .42-3.46(m,2H),2.69-2.71(m,2H),2.37-2.42(m,6H),2.14-2.15(s,2H ),1.60-1.66(m,2H),1.38-1.41(m,4H),1.26-1.28(m,58H),0.89(d,6H).

[0139] Example 34, Synthesis of Lipid Compound L-34

[0140] Compound 15-1 (12 mmol) and compound 34-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate. After purification on a silica gel column, the solvent was removed using a rotary evaporator to obtain compound 34-2.

[0141] Compound 34-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-34 (534 mg, 70.5% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),8.42-8.44(m,1H),7.64-7.66(m,1H),7.27-7.31(m,1H),4.45-4.49(m,1H),4.12-4.14 (m,2H),3.64-3.68(s,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,6H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0142] Example 35, Synthesis of Lipid Compound L-35

[0143] Compound 34-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 15-1 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-35 (505 mg, 60.0% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),8.42-8.44(m,1H),7.64-7.66(m,1H),7.27-7.31(m,1H),4.45-4.49(m,1H),3. 64-3.68(s,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,4H),1.47-1.49(m,8H),1.26-1.33(s,60H),0.89(d,12H).

[0144] Example 36, Synthesis of Lipid Compound L-36

[0145] Compound 1-3 (12 mmol) and compound 34-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 36-1.

[0146] Compound 36-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-36 (425 mg, 67.3% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),8.42-8.44(m,1H),7.64-7.66(m,1H),7.27-7.31(m,1H),4.12-4.14(m,4H),3 .64-3.68(s,2H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,8H),1.47-1.49(m,4H),1.26-1.33(s,36H),0.89(d,6H).

[0147] Example 37, Synthesis of Lipid Compound L-37

[0148] 1 mmol of compound 34-1 and 2.4 mmol of compound 27-1 were added to a Teflon-lined glass screw-cap vial and hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-37 (440 mg, 74.7% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),8.42-8.44(m,1H),7.64-7.66(m,1H),7.27-7.31(m,1H),3.61-3.63 (s,2H),3.43-3.47(m,2H),2.37-2.62(m,4H),2.13-2.17(m,2H),1.39-1.41(m,4H),1.25-1.27(s,48H),0.89(d,6H).

[0149] Example 38, Synthesis of Lipid Compound L-38

[0150] Compound 15-1 (12 mmol) and compound 38-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified on a silica gel column, and the solvent was removed using a rotary evaporator to obtain compound 38-2.

[0151] Compound 38-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-38 (515 mg, 66.8% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),7.73-7.77(m,1H),7.27-7.31(m,1H),4.45-4.49(m,1H),4.12-4.14(m,2H),3.64-3.68 (s,2H),2.40-2.44(m,3H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,6H),1.47-1.49(m,6H),1.26-1.33(s,50H),0.89(d,9H).

[0152] Example 39, Synthesis of Lipid Compound L-39

[0153] Compound 38-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 15-1 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-39 (603 mg, 70.5% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),7.73-7.77(m,1H),7.27-7.31(m,1H),4.45-4.49(m,1H),3.64-3.68(s,2H),2. 40-2.44(m,3H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,4H),1.47-1.49(m,8H),1.26-1.33(s,60H),0.89(d,12H).

[0154] Example 40, Synthesis of Lipid Compound L-40

[0155] Compound 1-3 (12 mmol) and compound 38-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate, purified by silica gel column, and the solvent was removed by rotary evaporation to obtain compound 40-1.

[0156] Compound 40-1 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-40 (436 mg, 67.6% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),7.73-7.77(m,1H),7.27-7.31(m,1H),4.12-4.14(m,4H),3.64-3.68(s,2H),2 .40-2.44(m,3H),2.36-2.40(m,4H),2.30-2.34(m,4H),1.58-1.66(m,8H),1.47-1.49(m,4H),1.26-1.33(s,36H),0.89(d,6H).

[0157] Example 41, Synthesis of Lipid Compound L-41

[0158] 1 mmol of compound 38-1 and 2.4 mmol of compound 27-1 were added to a Teflon-lined glass screw-cap vial and hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound L-41 (403 mg, 66.8% yield). 1H NMR(400MHz,Chloroform-d)δ8.61-8.63(m,1H),7.73-7.77(m,1H),7.27-7.31(m,1H),3.61-3.63(s,2H),3 .43-3.47(m,2H),2.37-2.62(m,7H),2.13-2.17(m,2H),1.39-1.41(m,4H),1.25-1.27(s,48H),0.89(d,6H).

[0159] Example 42 Synthesis of ionizable lipid CX (X=1-5) in control group

[0160] 1 mmol of compounds 42-1, 42-2, 42-3, 42-4, and 42-5 were mixed with 2.4 mmol of compound 15-1, added to a Teflon-lined glass screw-cap vial, and hydrothermally reacted at 70°C for 48 hours. After purification on a silica gel column, the solvent was removed on a rotary evaporator to yield lipid compounds CX (X = 1-5).

[0161] Example 43 Synthesis of ionizable lipid CX (X=6-7) in control group

[0162] Compound 42-2 (12 mmol) and compound 43-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate. After purification on a silica gel column, the solvent was removed using a rotary evaporator to obtain compound 43-2.

[0163] Compound 43-2 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound C-6.

[0164] Compound 42-1 (12 mmol) and compound 43-1 (10 mmol) were added to an acetonitrile solution (100 mL), and ground potassium carbonate (4.5 g) was added. The mixture was stirred at 70°C for 3 hours, after which the product was filtered to remove potassium carbonate. After purification on a silica gel column, the solvent was removed using a rotary evaporator to obtain compound 43-3.

[0165] Compound 43-3 (1 mmol) was dissolved in acetonitrile (10 ml) and stirred at room temperature. NaI (170 mg), K2CO3 (470 mg), and compound 17-2 (1.24 mmol) were then added to the reaction system in batches. The mixture was heated under reflux at 85°C with stirring for 2 h. After purification on a silica gel column, the solvent was removed on a rotary evaporator to obtain lipid compound C-7.

[0166] Example 44 Preparation of LNP lipid nanoparticles

[0167] Ionizable lipids LX (X = 1-41) or CX (X = 1-7), DSPC, cholesterol, and DMG-PEG 2000 were dissolved in ethanol at a molar ratio of 47.5:10.5:40.425:1.575, for a total lipid concentration of 12 mM. Ionizable lipids SM-102, DSPC, cholesterol, and DMG-PEG 2000 were dissolved in ethanol at a molar ratio of 50:10:38.5:1.5, for a total lipid concentration of 12 mM. mRNA containing a firefly luciferase or green fluorescent protein (eGFP) reporter gene was dissolved in citric acid-ammonium citrate buffer at pH 4.5 at an N:P ratio of 6:1. The ethanolic lipid solution and mRNA buffer were mixed at a volume ratio of 1:3 using a microfluidic device. The collected product was placed in a dialysis bag (molecular weight cutoff 100 KDa) and dialyzed in PBS at pH 7.4 for 12 hours. The mRNA-LNP was then concentrated using an ultrafiltration tube, and the mRNA was diluted to 150 μg / ml with 1XPBS and stored frozen.

[0168] Example 45 Preparation of Nucleic Acid Lipid Complex LPX

[0169] Ionizable lipids LX (X = 1-41) and CX (X = 1-7) were dissolved in an ethanol solution. Fluc-mRNA containing the firefly luciferase reporter gene was dissolved in a pH 4.5 citric acid-ammonium citrate buffer and mixed with the lipid ethanol solution at a mass ratio of 6:1. After mixing thoroughly, the mixture was allowed to stand for 15 minutes to obtain LX-LPX or CX-LPX.

[0170] Test example:

[0171] Experiment 1

[0172] Experiment Name: Characterization and Determination of Particle Size Encapsulation Efficiency of LX-LNP and SM102 Reference

[0173] Experimental materials: eGFP mRNA-LNP was prepared as in Example 44.

[0174] Experimental process: 1) Particle size analysis test: Use a quartz cuvette with a size of 10mm×10mm×40mm as a sample dish, and use DLS to test the particle size and distribution of the sample solution. The test is repeated twice with an interval of 30 seconds. The average of the two tests is used as the final data. 3) mRNA encapsulation efficiency determination: Use Quant-it TMThe encapsulation efficiency was determined using the RiboGreen RNA Assay Kit. a. Use the TE buffer in the kit to dilute the prepared eGFP mRNA-LNP suspension and PBS (negative control, equal volume of TE buffer) to 4 ng / μl to obtain the eGFP mRNA-LNP working solution. b. Continue to use TE buffer (or TE buffer containing 2% Triton-X100) to further dilute the eGFP mRNA-LNP working solution to an equal volume, mix well and let it stand at 37°C for 10 minutes (TE buffer without Triton-X100 is used to determine the unencapsulated free mRNA, while TE buffer containing 2% Triton-X100 is used to determine the Total mRNA in the eGFP mRNA-LNP working solution, which includes free mRNA and mRNA encapsulated in lipid nanoparticles). c. After calibrating the fluorescence intensity: concentration standard curve with the standard, pipette an appropriate amount of Quant-it TM RiboGreen RNA reagent (nucleic acid dye) was added to each sample and stained for 5 minutes. The stained samples were transferred to a microplate reader for analysis, and the mRNA content was accurately quantified using software. d. The mRNA encapsulation efficiency (EE%) in the lipid nanoparticles was calculated using the following formula: Encapsulation efficiency (EE%) = [1 – m(free mRNA): m(total mRNA)] × 100%.

[0175] Experimental results: As shown in Tables 2 to 6, the LX-LNP (X = 1 to 41) prepared by the present invention has a narrow particle size distribution, and the size meets the ideal nanovaccine size. At the same time, thanks to the ionizable lipids in the acidic buffer, mRNA can be well loaded, so the prepared eGFP mRNA-LNP has a high mRNA encapsulation efficiency. At the same time, taking L-9-LNP as an example, as shown in Figure 1, the prepared mRNA / L-9-LNP has a regular particle morphology.

[0176] Table 1

[0177] Table 2

[0178] Table 3

[0179] Table 4

[0180] Form 5

[0181] Experiment 2

[0182] Experiment Name: In vitro mRNA translation expression evaluation experiment

[0183] Experimental materials: eGFP mRNA-LNP prepared in Example 44, and Fluc-mRNA-LPX prepared in Example 45.

[0184] Experimental Procedure: DC2.4 cells were cultured in RPMI 1640 medium supplemented with 10% (v / v) fetal bovine serum (FBS) (Gibco) and 1% (v / v) P / S antibody until the logarithmic growth phase. 100,000 cells were seeded per well in a 24-well plate and transfected with LX-LNPs containing 2 μg of eGFP mRNA. Twenty-four hours after transfection, the cell culture medium was aspirated, and the cells were gently washed once with PBS. The percentage of positive cells in each group was analyzed by flow cytometry.

[0185] 293T cells were cultured in DMEM medium supplemented with 10% (v / v) fetal bovine serum (FBS) (Gibco) and 1% (v / v) P / S antibody until the logarithmic growth phase. 100,000 cells were seeded per well in a 24-well plate and transfected with LX-LPX containing 1 μg of FLuc-mRNA. Twenty-four hours after transfection, an equal volume of the cultured cells was mixed with Beyotime One-Lumi Firefly Luciferase Detection Reagent. After a 5-minute reaction, chemiluminescence detection was performed using a multi-function microplate reader.

[0186] Experimental Results: First, the effect of the position of the pyridine substituent on transfection efficiency was considered. As shown in Figure 2, para-substitution had the highest transfection efficiency. In contrast, ortho-substitution had lower transfection efficiency, which may be due to steric hindrance. The effect of the linker segment L1 was further investigated. As shown in Figure 3, side chain substitution of the linker segment reduced transfection efficiency. The effect of hydrophobic tails of different structures on in vitro cell transfection efficiency was further investigated. As shown in Figure 4, the length of the hydrophobic segments before and after the ester bond had little effect on cell transfection efficiency. The effect of different numbers of hydrophobic tails on transfection efficiency was also considered. As shown in Figure 5, the transfection efficiency of LNPs with four hydrophobic tails was significantly higher than that of LNPs with two hydrophobic tails. This may be because the increase in hydrophobic segments can enhance the interaction between LNPs and cell membranes. Compared with the commercially available SM102-LNP, the LNPs containing the novel ionizable pyridine-based lipids proposed in this patent invention significantly improve cell transfection efficiency.

[0187] On the basis of the above research, as shown in Figure 6, the present invention found that when the connecting segment is a methylene group, the transfection efficiency of the ionizable lipid compound is significantly improved. Then the connecting segment was fixed as a methylene group and the effects of substitutions at different positions on the pyridine group were further considered. As shown in Figure 7, the present invention found that substitution at position 3, i.e., the meta position, on the pyridine group has the best cell transfection efficiency, followed by para-position substitution (position 4), while ortho-position substitution (position 2) may have a lower transfection efficiency due to steric hindrance. The same conclusion can be obtained in both types of compounds. Based on the above surprising discovery, the pyridine group was further chemically modified. As shown in Figure 8, by performing an electron-donating methyl substitution at position 6 on the pyridine group, the reactivity of the pyridine group N can be further improved, and the cell transfection efficiency of the ionizable lipid can be further enhanced.

[0188] Experiment 3:

[0189] Experiment Name: Firefly luciferase mRNA expression evaluation experiment in mice

[0190] Experimental materials: luc mRNA-LNP prepared in Example 44

[0191] Experimental Procedure: 4-6 week old BALB / c mice were subcutaneously injected at the base of the tail with 20 μg of Luc-mRNA delivered via different delivery vectors. Eight hours after administration, 100 μL of 15 mg / mL luciferin was intraperitoneally injected. Ten minutes later, the distribution of fluorescent signals was observed using an IVIS mouse in vivo imager (PerkinElmer).

[0192] Experimental Results: To directly evaluate the translational efficiency of different LX-LNP delivery systems in mice, we used different delivery systems to encapsulate Luc-mRNA. As shown in Figure 9, compared to the commercially available SM102-LNP, the LNP containing the novel ionizable pyridyl lipid proposed in this patent significantly enhanced the efficient in vivo expression of the mRNA-encoded antigen. Furthermore, the LNP containing the novel ionizable pyridyl lipid exhibited minimal toxic side effects, and the mice maintained good survival and safety.

[0193] In summary, the present invention effectively overcomes various shortcomings of the prior art and has high industrial utilization value.

[0194] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the present invention. Anyone skilled in the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by one of ordinary skill in the art without departing from the spirit and technical principles disclosed herein are intended to be covered by the claims of the present invention.

Claims

1. An ionizable lipid compound, characterized in that The compound is of the following formula (1): G1 is pyridine, quinoline or its derivatives; L1 is selected from: G2 is the structural formula of the following formula (2) or (3): Wherein, L2 is C3-C9 alkylene; R1 and R2 are each independently C3-C9 alkyl; G3 is the structural formula of the following formula (4) or (5): Wherein, L3 is a C3-C9 alkylene group; R3 and R4 are each independently a C3-C9 alkyl group.

2. The ionizable lipid compound according to claim 1, characterized in that The -C(R1)R2 or -C(R3)R4 is selected from the following structures:

3. The ionizable lipid compound according to claim 1, characterized in that Includes the following compounds:

4. The use of the ionizable lipid compound according to claim 1 in the field of delivery, characterized in that: Applicable to a composition comprising an ionizable lipid compound, a stereoisomer thereof, a tautomer thereof or a pharmaceutically acceptable salt thereof.

5. Use of the ionizable lipid compound according to claim 4 in the field of delivery, characterized in that: The composition containing ionizable lipid compounds comprises: nucleic acid active molecules, lipid nanoparticles encapsulating the nucleic acid active molecules, and drug agents.

6. Use of the ionizable lipid compound according to claim 5 in the field of delivery, characterized in that: The lipid nanoparticles include, by molar percentage, 30-50% of one or more ionizable lipid compounds, 8-12% of auxiliary phospholipids, 35-60% of structural lipids and 1-3% of PEG lipids.

7. The use of an ionizable lipid compound according to claim 6, characterized in that: The auxiliary phospholipids include: one or more of DSPC, DOPE, DOPC, DOPS, DSPG, DPPG, DPPC, DGTS and lysophospholipids, preferably one or more selected from DSPC, DOPE, DOPC and DOPS, more preferably DSPC and / or DOPE.

8. The use of an ionizable lipid compound according to claim 6, characterized in that: The structural lipid is at least one selected from cholesterol, cholesterol ester, steroid hormones, steroid vitamins, bile acid, cholesterol, ergosterol, β-sitosterol and oxidized cholesterol derivatives, preferably at least one selected from cholesterol, cholesterol ester, steroid hormones, steroid vitamins and bile acid, more preferably cholesterol, even more preferably high-purity cholesterol, in particular injection-grade high-purity cholesterol, such as CHO-HP.

9. The use of an ionizable lipid compound according to claim 6, characterized in that: The PEG lipid comprises: at least one selected from DMG-PEG, DSG-PEG and DSPE-PEG, preferably PEG-DMG; preferably, the DMG-PEG is a polyethylene glycol (PEG) derivative of 1,2-dimyristyl glyceride; preferably, the average molecular weight of the PEG is about 2000 to 5000, preferably about 2000.

10. The use of an ionizable lipid compound according to claim 6, characterized in that: The nucleic acid active molecule is selected from mRNA, siRNA, ASO, saRNA, miRNA, and DNA.

11. Use of the ionizable lipid compound according to claim 5 in the field of nucleic acid delivery, characterized in that: The preparation method of the LNP is: dissolving an ionizable lipid compound, auxiliary phospholipids, structural lipids and PEG lipids in ethanol to obtain a lipid ethanol solution; mixing the lipid ethanol solution with a nucleic acid aqueous solution through device mixing to obtain lipid nanoparticles encapsulating nucleic acids.

Citation Information

Patent Citations

  • Ionizable lipid compound and application thereof in delivery field

    CN117088805A

  • Ionizable lipid compound and application thereof in field of nucleic acid delivery

    CN117843556A

  • Compounds and compositions for intracellular delivery of therapeutic agents

    US20220409536A1

  • Methods of making tolerogenic dendritic cells

    US20230112857A1

Cited By

  • Lipids and lipid nanoparticles

    WO2026003582A2